MEGen: Aphysiologically based pharmacokinetic model generator

Frontiers in Pharmacology

Volumn 2 NOV, Issue , 2011, Pages

  Loizou, George ^a   Hogg, Alex ^b  

^a HEALTH AND SAFETY LABORATORY   (United Kingdom)

^b Wandering Rock Limited   (United Kingdom)

Author keywords

Database; Equation; Generator; Pharmacokinetic; Physiologically based

Indexed keywords

ALCOHOL; ALCOHOL DEHYDROGENASE; CHLOROPRENE; GLUTATHIONE; VINYL CHLORIDE;

ALCOHOL METABOLISM; ARTICLE; COMPUTER PROGRAM; DATA BASE; EXPOSURE; GENETIC POLYMORPHISM; HUMAN; INFORMATION RETRIEVAL; LUNG BLOOD FLOW; MATHEMATICAL MODEL; NONHUMAN; PROCESS DEVELOPMENT; SIMULATION;

EID: 84860817075     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2011.00056     Document Type: Article

References (23)

1. Baldrick, P. (2003). Toxicokinetics in preclinical evaluation. Drug Discov. Today 8, 127-133.
2. Barton, H. A., Chiu, W. A., Setzer, R. W., Andersen, M. E., Bailer, A. J., Bois, F. Y., Dewoskin, R. S., Hays, S., Johanson, G., Jones, N., Loizou, G., Macphail, R. C., Portier, C. J., Spendiff, M., and Tan, Y. M. (2007). Characterizing uncertainty and variability in physiologically-based pharmacokinetic (PBPK) models: state of the science and needs for research and implementation. Toxicol. Sci. 99, 395-402.
3. Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., and Beliles, R. P. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13, 407-484.
4. Chiu, W. A., Barton, H. A., Dewoskin, R. S., Schlosser, P., Thompson, C. M., Sonawane, B., Lipscomb, J. C., and Krishnan, K. (2007). Evaluation of physiologically based pharmacokinetic models for use in risk assessment. J. Appl. Toxicol. 27, 218-237.
5. Clark, L. H., Setzer, R. W., and Barton, H. A. (2004). Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment. Risk Anal. 24, 1697-1717.
6. Clewell, H. J., and Andersen, M. E. (1985). Risk Assessment extrapolations and physiological modeling. Toxicol. Ind. Health 1, 111-131.
7. Clewell, H. J., Gentry, P. R., Gearhart, J. M., Allen, B. C., and Andersen, M. E. (2001). Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Sci. Total Environ. 274, 37-66.
8. DeJongh, J., Nordin-Andersson, M., Ploeger, B. A., and Forsby, A. (1999). Estimation of systemic toxicity of acrylamide by integration on in vitro toxicity data with kinetic simulations. Toxicol. Appl. Pharmacol. 158, 261-268.
9. D'Souza, R. W., Francis, W. R., and Andersen, M. E. (1988). Physiological model for tissue glutathione depletion and increased resynthesis after ethylene dichloride exposure. J. Pharmacol. Exp. Ther. 245, 563-568.
10. Forsby, A., and Blaauboer, B. (2007). Integration of in vitro neurotoxicity data with biokinetic modelling for the estimation of in vivo neurotoxicity. Hum. Exp. Toxicol. 26, 333-338.
11. Gargas, M. L., Andersen, M. E., and Clewell, III. H. J. (1986). A physiologically based simulation approach for determining metabolic constants from gas uptake data. Toxicol. Appl. Pharmacol. 86, 341-352.
12. Himmelstein, M. W., Carpenter, S. C., Evans, M. V., Hinderliter, P. M., and Kenyon, E. M. (2004). Kinetic modeling of beta-chloroprene metabolism: II. The application of physiologically based modeling for cancer dose response analysis. Toxicol. Sci. 79, 28-37.
13. ICH. (1995). CPMP/ICH/384/95. Note for Guidance on Toxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies. London: European Medicines Agency.
14. Jamei, M., Dickinson, G. L., and Rostami-Hodjegan, A. (2009). A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs. 'top-down' recognition of covariates. Drug Metab. Pharmacokinet. 24, 53-75.
15. Krishnan, K., and Andersen, M. E. (1994). "Physiologically based pharmacokinetic modeling in toxicology," in Principals and Methods of Toxicology ed.A.W.Hayes(New York: Raven Press Ltd.), 149-188.
16. Loizou, G. D., Eldirdiri, N. I., and King, L. J. (1996). Physiologically based pharmacokinetics of uptake by inhalation of a series of 1,1,1trihaloethanes: correlation with various physicochemical parameters. Inhal. Toxicol. 8, 1-19.
17. Loizou, G. D., and Spendiff, M. (2004). A human PBPK model for ethanol describing inhibition of gastric motility. J. Mol. Histol. 35, 687-696.
18. Loizou, G. D., Spendiff, M., Barton, H. A., Bessems, J., Bois, F. Y., Bouvier, d. Y., Buist, H., Clewell, III. H., Gundert-Remy, U., Goerlitz, G., Meek, B., and Schmitt, W. (2008). Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. Regul. Toxicol. Pharmacol. 50, 400-411.
19. Pastino, G. M., Flynn, E. J., and Sultatos, L. G. (2000). Genetic polymorphisms in ethanol metabolism: issues and goals for physiologically based pharmacokinetic modeling. Drug Chem. Toxicol. 23, 179-201.
20. Rostami-Hodjegan, A.,and Tucker, G. T. (2007). Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6, 140-148.
21. Shiran, M. R., Proctor, N. J., Howgate, E. M., Rowland-Yeo, K., Tucker, G. T., and Rostami-Hodjegan, A. (2006). Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs. allometric scaling. Xenobiotica 36, 567-580.
22. Sultatos, L. G., Pastino, G. M., Rosenfeld, C. A., and Flynn, E. J. (2004). Incorporation of the genetic control of alcohol dehydrogenase into a physiologically based pharmacokinetic model for ethanol in humans. Toxicol. Sci. 78, 20-31.
23. Thompson, C. M., Sonawane, B., Barton, H. A., DeWoskin, R. S., Lipscomb, J. C., Schlosser, P., Chiu, W. A., and Krishnan, K. (2008). Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J. Toxicol. Environ. Health B Crit. Rev. 11, 519-547.